CD8A and myeloid sarcoma: Given that other disorders (e.g., oncological malignancies) also demonstrate dysregulated CD8+ memory T cells, it is necessary to evaluate their specificity, sensitivity, cytotoxicity, and negative co-stimulation to demonstrate whether these markers might be specific for MS.